Press Releases for SVNT

Press Releases
BenchmarkJournal.Com Free Analyst Review for VPRT, ARCC, STAR, VRNM, XOMA and SVNT
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results ; Ends First Half of 2009 With $76.6M in Cash and Short-Term Investments
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
Lawrence Gyenes Appointed Chief Financial Officer of Columbia Laboratories
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Savient Announces Election of Dr. Ginger D. Constantine to Board of Directors
Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress
Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
Savient Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 14, 2009
Savient Pharmaceuticals to Hold First Quarter 2009 Financial Results Conference Call On Thursday, May 7, 2009
Beacon Equity Issues Trade Alerts on Market Movers: BBI, SVNT, SI, GILD, CHRS, RIMM
Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
Savient Announces Appointment of David Gionco as Chief Financial Officer
Savient Provides Update on Pegloticase BLA
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
BenchmarkJournal.Com (Complimentary) Analyst Review for PSUN, COST, HSNI and SVNT
Pegloticase BLA Filing Accepted for Priority Review by FDA
Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Savient Pharmaceuticals, Inc.
Bull & Lifshitz, LLP Announces Investigation On Behalf of Certain Investors of Savient Pharmaceuticals, Inc. -- SVNT
Izard Nobel LLP Announces Class Action Lawsuit Against Savient Pharmaceuticals, Inc.
Federman &Amp; Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)
Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 From Investment in Savient Pharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 26, 2009 Lead Plaintiff Deadline
Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Savient Pharmaceuticals, Inc.
Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Savient Submits Biologics License Application (BLA) for pegloticase
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
Savient to Host Conference Call on Pegloticase Scientific Presentations
Savient Provides Update on Business Development Plans and BLA Filing
New Pegloticase and Treatment Failure Gout Data to be Featured in Six Abstracts At American College of Rheumatology 72nd Annual Scientific Meeting
Savient Pharmaceuticals Reports Second Quarter 2008 Financial Results
Savient Pharmaceuticals to Hold Second Quarter Financial Results Conference Call on Thursday, August 7, 2008
Savient Announces U.S. Court of Appeals Affirmation of the Dismissal of Securities Class Action Complaint
Savient Pharmaceuticals to Present At Jefferies 2nd Annual Healthcare Conference On June 26th
Christopher G. Clement, President and CEO of Savient Pharmaceuticals, Named Ernst & Young Entrepreneur of The Year 2008 Award Finalist in New Jersey
BellwetherReport.com Analyst Report on JOYG, SVNT, CWTR and BBY
Savient Pharmaceuticals, Inc. (SVNT) Chief Business Officer to Ring the NASDAQ Stock Market Opening Bell - May 27 2008 1:00AM
Savient Pharmaceuticals to Present At Citi Investment Research Global Healthcare Conference On May 22nd
Savient Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 2 2008 5:07AM
Savient Reports Favorable Interim Data from Puricase(R) (pegloticase) Open Label Extension Study - Jun 2 2008 5:07AM
Savient Provides Update On Puricase(R) (pegloticase) Biologics License Application
Savient Pharmaceuticals to Hold First Quarter 2008 Financial Results Conference Call On Thursday, May 8, 2008